Polaryx Therapeutics, Inc. Common Stock (PLYX )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol PLYX
- Company Polaryx Therapeutics, Inc. Common Stock
- Price $20.04
- Changes Percentage -42.74
- Change -14.96
- Day Low $17.12
- Day High $33.6
- Year High $48.91
- Year Low $16.7
- Market Cap $943,686,867
- Price Avg 50 EMA (D) $35
- Price Avg 200 EMA (D) $35
- Exchange NASDAQ
- Volume 39,054
- Average Volume 25,300
- Open $31
- Previous Close $35
- EPS 0
- PE 0.00
- Earnings Announcement 1970-01-01 00:00:00
- Shares Outstanding $47,090,163
Company brief: POLARYX THERAPEUTICS, INC. COMMON STOCK (PLYX )
- Healthcare
- Biotechnology
- Alex Yang
- https://polaryx.com
- US
- N/A
- 02-02-2026
- US73110F1003
Polaryx Therapeutics, Inc., operates as a biotech company that develops small molecule therapeutics for lysosomal storage disorders and neurodegenerative disorders. Its pipeline includes PLX-100, a combination of PLX-200 and a supplement for late infantile neuronal ceroid lipofuscinosis (LINCL) and other forms of NCL; PLX-200, a repurposed drug that is used to treat other diseases in adults and children; and PLX-300, a drug isolated from an edible plant that activates PPARa, which enhances production of transcription factor EB. The company was founded in 2014 and is based in Paramus, New Jersey.